157 related articles for article (PubMed ID: 30206312)
1. The STAT3 inhibitor S3I-201 suppresses fibrogenesis and angiogenesis in liver fibrosis.
Wang Z; Li J; Xiao W; Long J; Zhang H
Lab Invest; 2018 Dec; 98(12):1600-1613. PubMed ID: 30206312
[TBL] [Abstract][Full Text] [Related]
2. Sorafenib and its derivative SC-1 exhibit antifibrotic effects through signal transducer and activator of transcription 3 inhibition.
Su TH; Shiau CW; Jao P; Liu CH; Liu CJ; Tai WT; Jeng YM; Yang HC; Tseng TC; Huang HP; Cheng HR; Chen PJ; Chen KF; Kao JH; Chen DS
Proc Natl Acad Sci U S A; 2015 Jun; 112(23):7243-8. PubMed ID: 26039995
[TBL] [Abstract][Full Text] [Related]
3. A histone deacetylase inhibitor, largazole, decreases liver fibrosis and angiogenesis by inhibiting transforming growth factor-β and vascular endothelial growth factor signalling.
Liu Y; Wang Z; Wang J; Lam W; Kwong S; Li F; Friedman SL; Zhou S; Ren Q; Xu Z; Wang X; Ji L; Tang S; Zhang H; Lui EL; Ye T
Liver Int; 2013 Apr; 33(4):504-15. PubMed ID: 23279742
[TBL] [Abstract][Full Text] [Related]
4. Micellar nano-carriers for the delivery of STAT3 dimerization inhibitors to melanoma.
Soleimani AH; Garg SM; Paiva IM; Vakili MR; Alshareef A; Huang YH; Molavi O; Lai R; Lavasanifar A
Drug Deliv Transl Res; 2017 Aug; 7(4):571-581. PubMed ID: 28290050
[TBL] [Abstract][Full Text] [Related]
5. Sorafenib reduces steatosis-induced fibrogenesis in a human 3D co-culture model of non-alcoholic fatty liver disease.
Romualdo GR; Da Silva TC; de Albuquerque Landi MF; Morais JÁ; Barbisan LF; Vinken M; Oliveira CP; Cogliati B
Environ Toxicol; 2021 Feb; 36(2):168-176. PubMed ID: 32918399
[TBL] [Abstract][Full Text] [Related]
6. New insights into the antifibrotic effects of sorafenib on hepatic stellate cells and liver fibrosis.
Wang Y; Gao J; Zhang D; Zhang J; Ma J; Jiang H
J Hepatol; 2010 Jul; 53(1):132-44. PubMed ID: 20447716
[TBL] [Abstract][Full Text] [Related]
7. A novel STAT3 inhibitor, S3I-201, attenuates renal interstitial fibroblast activation and interstitial fibrosis in obstructive nephropathy.
Pang M; Ma L; Gong R; Tolbert E; Mao H; Ponnusamy M; Chin YE; Yan H; Dworkin LD; Zhuang S
Kidney Int; 2010 Aug; 78(3):257-68. PubMed ID: 20520592
[TBL] [Abstract][Full Text] [Related]
8. Antifibrotic effects of luteolin on hepatic stellate cells and liver fibrosis by targeting AKT/mTOR/p70S6K and TGFβ/Smad signalling pathways.
Li J; Li X; Xu W; Wang S; Hu Z; Zhang Q; Deng X; Wang J; Zhang J; Guo C
Liver Int; 2015 Apr; 35(4):1222-33. PubMed ID: 25040634
[TBL] [Abstract][Full Text] [Related]
9. Physalin D attenuates hepatic stellate cell activation and liver fibrosis by blocking TGF-β/Smad and YAP signaling.
Xiang D; Zou J; Zhu X; Chen X; Luo J; Kong L; Zhang H
Phytomedicine; 2020 Nov; 78():153294. PubMed ID: 32771890
[TBL] [Abstract][Full Text] [Related]
10. Knockdown of LOXL1 inhibits TGF-β1-induced proliferation and fibrogenesis of hepatic stellate cells by inhibition of Smad2/3 phosphorylation.
Ma L; Zeng Y; Wei J; Yang D; Ding G; Liu J; Shang J; Kang Y; Ji X
Biomed Pharmacother; 2018 Nov; 107():1728-1735. PubMed ID: 30257391
[TBL] [Abstract][Full Text] [Related]
11. Oridonin inhibits hepatic stellate cell proliferation and fibrogenesis.
Bohanon FJ; Wang X; Ding C; Ding Y; Radhakrishnan GL; Rastellini C; Zhou J; Radhakrishnan RS
J Surg Res; 2014 Jul; 190(1):55-63. PubMed ID: 24742622
[TBL] [Abstract][Full Text] [Related]
12. The antiprotozoal drug nitazoxanide improves experimental liver fibrosis in mice.
Liu KX; Wang ZY; Ying YT; Wei RM; Dong DL; Sun ZJ
Biochem Pharmacol; 2024 Jun; 224():116205. PubMed ID: 38615918
[TBL] [Abstract][Full Text] [Related]
13. Astaxanthin prevents TGFβ1-induced pro-fibrogenic gene expression by inhibiting Smad3 activation in hepatic stellate cells.
Yang Y; Kim B; Park YK; Koo SI; Lee JY
Biochim Biophys Acta; 2015 Jan; 1850(1):178-85. PubMed ID: 25450180
[TBL] [Abstract][Full Text] [Related]
14. Sauchinone attenuates liver fibrosis and hepatic stellate cell activation through TGF-β/Smad signaling pathway.
Lee JH; Jang EJ; Seo HL; Ku SK; Lee JR; Shin SS; Park SD; Kim SC; Kim YW
Chem Biol Interact; 2014 Dec; 224():58-67. PubMed ID: 25451574
[TBL] [Abstract][Full Text] [Related]
15. STAT3-mediated attenuation of CCl4-induced mouse liver fibrosis by the protein kinase inhibitor sorafenib.
Deng YR; Ma HD; Tsuneyama K; Yang W; Wang YH; Lu FT; Liu CH; Liu P; He XS; Diehl AM; Gershwin ME; Lian ZX
J Autoimmun; 2013 Oct; 46():25-34. PubMed ID: 23948302
[TBL] [Abstract][Full Text] [Related]
16. A novel small-molecule disrupts Stat3 SH2 domain-phosphotyrosine interactions and Stat3-dependent tumor processes.
Zhang X; Yue P; Fletcher S; Zhao W; Gunning PT; Turkson J
Biochem Pharmacol; 2010 May; 79(10):1398-409. PubMed ID: 20067773
[TBL] [Abstract][Full Text] [Related]
17. Signal transducer and activator of transcription 3 (STAT3) inhibitor, S3I-201, acts as a potent and non-selective alkylating agent.
Ball DP; Lewis AM; Williams D; Resetca D; Wilson DJ; Gunning PT
Oncotarget; 2016 Apr; 7(15):20669-79. PubMed ID: 26942696
[TBL] [Abstract][Full Text] [Related]
18. Decursin attenuates hepatic fibrogenesis through interrupting TGF-beta-mediated NAD(P)H oxidase activation and Smad signaling in vivo and in vitro.
Choi YJ; Kim DH; Kim SJ; Kim J; Jeong SI; Chung CH; Yu KY; Kim SY
Life Sci; 2014 Jul; 108(2):94-103. PubMed ID: 24880074
[TBL] [Abstract][Full Text] [Related]
19. PTK787/ZK22258 attenuates stellate cell activation and hepatic fibrosis in vivo by inhibiting VEGF signaling.
Liu Y; Lui EL; Friedman SL; Li L; Ye T; Chen Y; Poon RT; Wo J; Kok TW; Fan ST
Lab Invest; 2009 Feb; 89(2):209-21. PubMed ID: 19114984
[TBL] [Abstract][Full Text] [Related]
20. Src-homology protein tyrosine phosphatase-1 agonist, SC-43, reduces liver fibrosis.
Su TH; Shiau CW; Jao P; Yang NJ; Tai WT; Liu CJ; Tseng TC; Yang HC; Liu CH; Huang KW; Hu TC; Huang YJ; Wu YM; Chen LJ; Chen PJ; Chen DS; Chen KF; Kao JH
Sci Rep; 2017 May; 7(1):1728. PubMed ID: 28496142
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
